Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib

References

• Baum M, Budzar AU, Cuzick J, et al. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–9
   PubMed Web of Science ®Google Scholar
• Bennett A, Charlier EM, Mcdonald AM, et al. (1977). Prostaglandins and breast cancer. Lancet 2:624–6
   PubMed Web of Science ®Google Scholar
• Brodie AM, Lu Q, Long BJ, et al. (2001). Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79:41–7
   PubMed Web of Science ®Google Scholar
• Buzdar AU. (2003). ‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview. J Steroid Biochem Mol Biol 86:399–403
   PubMed Web of Science ®Google Scholar
• Chang SH, Liu CH, Conway R, et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Nat Acad Sci USA 101:591–6
   PubMed Web of Science ®Google Scholar
• Chow LW, Loo WT, Toi M. (2005). Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother 59:281–4
   Web of Science ®Google Scholar
• Delafuente JC. (2003). Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48:133–43
   PubMed Web of Science ®Google Scholar
• Falandry C, Debled M, Bachelot T, et al. (2009). Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 116:501–8
   PubMed Web of Science ®Google Scholar
• Gluck S. (2002). Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Cancer 95:2442–3. author reply 3–4
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Jansson A, Holmlund B, et al. (2006). Expression of COX-2 and steroid converting enzymes in breast cancer. Oncol Rep 16:219–24
   PubMed Web of Science ®Google Scholar
• Herrero-Zazo M, Segura-Bedmar I, Martínez P. (2016). Conceptual models of drug–drug interactions: a summary of recent efforts. Knowl-Based Syst 114:99–107
   Web of Science ®Google Scholar
• Li Q, Wang D, Jing L, Ping C. (2011). Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 11:277
   PubMed Web of Science ®Google Scholar
• Liu CH. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563–9
   PubMed Web of Science ®Google Scholar
• Ma B, Zhang Y, Gu L, et al. (2015). Comparative pharmacokinetics of cyclophosphamide administration alone and combination with vitamin B6 in rats. Biomed Chromatogr 29:62–7
   PubMed Web of Science ®Google Scholar
• Marsh S, Liu G. (2009). Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv Drug Delivery Rev 61:381–7
   PubMed Web of Science ®Google Scholar
• Müller-Decker K, Berger I, Ackermann K, et al. (2005). Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol 166:575–84
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, et al (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18:3758
   PubMed Web of Science ®Google Scholar
• Prosperi JR, Robertson FM. (2006). Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 81:55–70
   PubMed Web of Science ®Google Scholar
• Ranger GS, Mokbel K. (2003). COX-2 inhibitors and breast cancer. ANZ J Surg 73:565–6
   PubMed Web of Science ®Google Scholar
• Regulski M, Regulska K, Prukala W, et al. (2016). COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discov Today 21:598–615
   PubMed Web of Science ®Google Scholar
• Sever B, Altintop MD, Kus G, et al. (2016). Indomethacin based new triazolothiadiazine derivatives: synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies. Eur J Med Chem 113:179–86
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30
   PubMed Web of Science ®Google Scholar
• Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW. (2008). Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids 73:104–11
   PubMed Web of Science ®Google Scholar
• Tao Z, Shi A, Lu C, et al. (2015). Breast cancer: epidemiology and etiology. Cell Biochem Biophys 72:333–8
   PubMed Web of Science ®Google Scholar
• U.S. (2001). Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Nonanalytic Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Available from: http://www.fda.gov/cvm
   Google Scholar
• Umeyama Y, Fujioka Y, Okuda T. (2014). Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information. Xenobiotica 44:1135–44
   PubMed Web of Science ®Google Scholar
• Werner U, Werner D, Rau T, et al. (2003). Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 74:130–7
   PubMed Web of Science ®Google Scholar
• Xiao J, Wang T, Li P, et al. (2016). Development of two step liquid—liquid extraction tandem UHPLC—MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. J Chromatogr B 1028:33–41
   PubMed Web of Science ®Google Scholar
• Xie X, Miao J, Sun W, et al. (2016). Simultaneous determination and pharmacokinetic study of four phenolic acids in rat plasma using UFLC-MS/MS after intravenous administration of salvianolic acid for injection. J Pharm Biomed Anal 134:53–9
   PubMed Web of Science ®Google Scholar
• Yoshinaka R, Shibata MA, Morimoto J, et al. (2006). COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res 26:4245–54
   PubMed Web of Science ®Google Scholar